Semaglutide is a GLP-1 receptor agonist available as weekly injection (Ozempic for diabetes, Wegovy for weight management) or daily oral tablet (Rybelsus for diabetes only)
If youve already lost weight on a GLP-1, your healthcare provider can document that you met the eligibility requirements when you began treatment
However, this approach is not medically advised, especially for weight loss medications
Although they are marketed as next-generation biohacks and research chemicals, many peptides are not approved for human use and lack basic clinical testing
Nauck, [email protected] This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Faster development and commercialization are also being facilitated by regulatory support for innovative treatments and accelerated approval processes for ground-breaking medications